Department of Hematology and Oncology, University of Yamanashi, Japan.
Intern Med. 2024 Mar 15;63(6):843-846. doi: 10.2169/internalmedicine.2171-23. Epub 2023 Aug 2.
Interferon is an emerging treatment option for myeloproliferative neoplasms (MPNs), especially for polycythemia vera (PV). Previous studies of interferon used therapeutically for hepatitis C have demonstrated that one of the most important adverse events associated with interferon treatment is thyroid dysfunction, and a management strategy for thyroid dysfunction has been established. However, whether or not the recommendation is also suitable for MPN settings is unclear. In this study, one PV patient developed silent thyroiditis during a phase 2 study of ropeginterferon α-2b. This case suggests that thyroid dysfunction is an important clinical issue to consider in interferon treatment for PV.
干扰素是骨髓增生性肿瘤（MPN）的一种新兴治疗选择，特别是对真性红细胞增多症（PV）。既往用于治疗丙型肝炎的干扰素治疗研究表明，与干扰素治疗相关的最重要的不良事件之一是甲状腺功能障碍，并且已经建立了甲状腺功能障碍的管理策略。然而，该建议是否也适用于 MPN 环境尚不清楚。在这项研究中，一名 PV 患者在罗匹尼罗干扰素α-2b 的 2 期研究中发生了无症状甲状腺炎。该病例提示甲状腺功能障碍是干扰素治疗 PV 时需要考虑的一个重要临床问题。
